David E. Lanfear

7.9k total citations · 2 hit papers
182 papers, 4.4k citations indexed

About

David E. Lanfear is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Biomedical Engineering. According to data from OpenAlex, David E. Lanfear has authored 182 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 109 papers in Cardiology and Cardiovascular Medicine, 48 papers in Surgery and 41 papers in Biomedical Engineering. Recurrent topics in David E. Lanfear's work include Heart Failure Treatment and Management (78 papers), Mechanical Circulatory Support Devices (41 papers) and Cardiac Structural Anomalies and Repair (33 papers). David E. Lanfear is often cited by papers focused on Heart Failure Treatment and Management (78 papers), Mechanical Circulatory Support Devices (41 papers) and Cardiac Structural Anomalies and Repair (33 papers). David E. Lanfear collaborates with scholars based in United States, Netherlands and Canada. David E. Lanfear's co-authors include L. Keoki Williams, Karen Wells, Edward L. Peterson, Celeste T. Williams, John A. Spertus, Manel Pladevall, Robert J. Brewer, Jeffrey A. Morgan, Cristina Tita and Hassan Nemeh and has published in prestigious journals such as JAMA, Circulation and Nature Medicine.

In The Last Decade

David E. Lanfear

175 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association

2016 239 citations David E. Lanfear et al. Circulation profile →
The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial

2022 158 citations John A. Spertus, Mary C. Birmingham et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David E. Lanfear United States	36	1.9k	1.2k	900	769	768	182	4.4k
Savina Nodari Italy	32	4.0k 2.2×	901 0.7×	450 0.5×	487 0.6×	449 0.6×	192	5.5k
Mona Fiuzat United States	46	5.3k 2.8×	800 0.7×	419 0.5×	587 0.8×	510 0.7×	184	7.1k
Vasiliki V. Georgiopoulou United States	37	3.1k 1.6×	664 0.5×	437 0.5×	292 0.4×	529 0.7×	103	4.4k
Nicholas M. Selby United Kingdom	37	1.3k 0.7×	1.6k 1.3×	261 0.3×	447 0.6×	254 0.3×	145	6.3k
Michel White Canada	44	5.6k 3.0×	1.3k 1.0×	373 0.4×	837 1.1×	378 0.5×	204	7.4k
Salvatore Di Somma Italy	34	1.6k 0.8×	1.1k 0.9×	690 0.8×	289 0.4×	477 0.6×	167	4.0k
Andrew P. Ambrosy United States	36	4.9k 2.6×	848 0.7×	516 0.6×	411 0.5×	241 0.3×	200	6.3k
Patrick Rossignol France	39	2.6k 1.4×	1.1k 0.9×	382 0.4×	785 1.0×	361 0.5×	182	5.7k
Filippos Triposkiadis Greece	35	3.8k 2.0×	741 0.6×	353 0.4×	591 0.8×	328 0.4×	217	5.4k
Phillip D. Levy United States	36	2.5k 1.3×	695 0.6×	290 0.3×	373 0.5×	211 0.3×	253	4.6k

Countries citing papers authored by David E. Lanfear

Since Specialization

Citations

This map shows the geographic impact of David E. Lanfear's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David E. Lanfear with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David E. Lanfear more than expected).

Fields of papers citing papers by David E. Lanfear

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David E. Lanfear. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David E. Lanfear. The network helps show where David E. Lanfear may publish in the future.

Co-authorship network of co-authors of David E. Lanfear

This figure shows the co-authorship network connecting the top 25 collaborators of David E. Lanfear. A scholar is included among the top collaborators of David E. Lanfear based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David E. Lanfear. David E. Lanfear is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Luzum, Jasmine A., et al.. (2025). The Beta‐Blocker Pharmacogenetic Puzzle: More Pieces of Evidence for Pharmacodynamic Candidate Variants. Clinical and Translational Science. 18(5). e70239–e70239. 1 indexed citations

Duarte, Julio D., Cameron D. Thomas, Craig R. Lee, et al.. (2024). Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta‐Blocker Therapy. Clinical Pharmacology & Therapeutics. 116(4). 939–947. 22 indexed citations

Lanfear, David E., et al.. (2024). Equal Treatment, Unequal Outcomes? Debunking the Racial Disparity in Renin Angiotensin Aldosterone System Inhibitor–Associated Reduction in Heart Failure Hospitalizations. Journal of Cardiac Failure. 31(5). 800–809. 1 indexed citations

Kaltenbach, Lisa A., Bradi B. Granger, Gregg C. Fonarow, et al.. (2024). Access to Mobile Health Interventions Among Patients Hospitalized With Heart Failure: Insights Into the Digital Divide From the CONNECT-HF mHealth Substudy. Circulation Heart Failure. 17(2). e011140–e011140. 1 indexed citations

Shoji, Satoshi, Lisa A. Kaltenbach, Bradi B. Granger, et al.. (2024). Guideline‐Directed Medical Therapy After Hospitalization for Acute Heart Failure: Insights From the CONNECT‐HF. Journal of the American Heart Association. 13(24). e036998–e036998. 1 indexed citations

Luzum, Jasmine A., Alessandra M. Campos‐Staffico, Jia Li, et al.. (2023). Genome-Wide Association Study of Beta-Blocker Survival Benefit in Black and White Patients with Heart Failure with Reduced Ejection Fraction. Genes. 14(11). 2019–2019. 1 indexed citations

Gui, Hongsheng, W.H. Wilson Tang, Stephan Francke, et al.. (2023). Common Variants on FGD5 Increase Hazard of Mortality or Rehospitalization in Patients With Heart Failure From the ASCEND-HF Trial. Circulation Heart Failure. 16(9). e010438–e010438. 7 indexed citations

Hannawi, Bashar, Edward L. Peterson, Hongsheng Gui, et al.. (2023). Evaluation of a New Aptamer-Based Array for Soluble Suppressor of Tumorgenicity (ST2) and N-terminal Pro-B-Type Natriuretic Peptide (NTproBNP) in Heart Failure Patients. Journal of Cardiovascular Translational Research. 16(6). 1343–1348. 1 indexed citations

Spertus, John A., Mary C. Birmingham, Michael E. Nassif, et al.. (2022). The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nature Medicine. 28(4). 809–813. 158 indexed citations breakdown →

10.

Cascino, Thomas, Monica Colvin, David E. Lanfear, et al.. (2022). Racial Inequities in Access to Ventricular Assist Device and Transplant Persist After Consideration for Preferences for Care: A Report From the REVIVAL Study. Circulation Heart Failure. 16(1). e009745–e009745. 33 indexed citations

11.

Roy, Bipradas, Shailendra Giri, David E. Lanfear, et al.. (2022). Aldehyde Dehydrogenase 2 Activator Augments the Beneficial Effects of Empagliflozin in Mice with Diabetes-Associated HFpEF. International Journal of Molecular Sciences. 23(18). 10439–10439. 9 indexed citations

12.

Selvaraj, Senthil, Zhuxuan Fu, Philip G. Jones, et al.. (2022). Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF. Circulation. 146(11). 808–818. 62 indexed citations

13.

Spertus, John A., Mary C. Birmingham, Javed Butler, et al.. (2021). Novel Trial Design: CHIEF-HF. Circulation Heart Failure. 14(3). e007767–e007767. 22 indexed citations

14.

Luzum, Jasmine A., Michael P. Dorsch, Edward L. Peterson, et al.. (2021). Survival Association of Angiotensin Inhibitors in Heart Failure With Reduced Ejection Fraction: Comparisons Using Self-Identified Race and Genomic Ancestry. Journal of Cardiac Failure. 28(2). 215–225. 2 indexed citations

15.

Richards, Allison L., Katherine Rhodes, Michelle C. Ward, et al.. (2021). Functional dynamic genetic effects on gene regulation are specific to particular cell types and environmental conditions. eLife. 10. 34 indexed citations

16.

Gui, Hongsheng, Ruicong She, Jasmine A. Luzum, et al.. (2021). Plasma Proteomic Profile Predicts Survival in Heart Failure With Reduced Ejection Fraction. Circulation Genomic and Precision Medicine. 14(3). e003140–e003140. 16 indexed citations

17.

Lala, Anuradha, Palak Shah, Shokoufeh Khalatbari, et al.. (2021). Frailty Measures of Patient-reported Activity and Fatigue May Predict 1-year Outcomes in Ambulatory Advanced Heart Failure: A Report From the REVIVAL Registry. Journal of Cardiac Failure. 28(5). 765–774. 3 indexed citations

18.

Bayés‐Genís, Antoni, Peter P. Liu, David E. Lanfear, et al.. (2020). Omics phenotyping in heart failure: the next frontier. European Heart Journal. 41(36). 3477–3484. 44 indexed citations

19.

Luzum, Jasmine A., Edward L. Peterson, Hongsheng Gui, et al.. (2019). Association of Regulatory Genetic Variants for Protein Kinase Cα with Mortality and Drug Efficacy in Patients with Heart Failure. Cardiovascular Drugs and Therapy. 33(6). 693–700. 1 indexed citations

20.

Mital, Seema, Kiran Musunuru, Vidu Garg, et al.. (2016). Enhancing Literacy in Cardiovascular Genetics: A Scientific Statement From the American Heart Association. Circulation Cardiovascular Genetics. 9(5). 448–467. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact